Sanofi-aventis has agreed to pay up to US$375 M to Metabolex to license a novel oral therapy in Phase II development for the treatment of type 2 diabetes, MBX-2982. It has also announced a partnership with the Juvenile Diabetes Research Foundation to fund research to tackle type 1 diabetes.